Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials - PubMed
2 hours ago
- #bispecific antibodies
- #treatment-related adverse events
- #meta-analysis
- Meta-analysis includes 104 clinical trials with 10,353 patients, covering both haematological malignancies and solid tumours treated with CD3-based T cell-engaging bispecific antibodies.
- Overall incidence of all-grade treatment-related adverse events is high for both haematological malignancies (97.5%) and solid tumours (97.9%), with grade 3 or worse events more common in haematological cancers (70.3% vs. 45.3%).
- Cytokine release syndrome is the most frequent all-grade adverse event across both cancer types, while neutropenia is most common grade 3 or worse event in haematological malignancies and increased γ-glutamyltransferase in solid tumours.
- Treatment-related deaths occur in 1.0% of patients, primarily due to infections and organ failures such as sepsis, pneumonia, and respiratory failure.
- The study highlights variability in toxicity profiles across cancer types and antibody classes, providing a basis for optimising patient management in clinical practice.